Endocrine Abstracts

Abstract: Obesity has reached epidemic proportions globally. At least 2.8 million people die each year as a result of being overweight or obese, the biggest burden being obesity-related diseases. Glucagon like peptide 1 (GLP-1) targeted therapies show the greatest potential for intervention and are approved as weight loss agents. However not all patients respond to GLP-1 therapy. Understanding the mechanisms of bodyweight regulation and their role in GLP-1 responders vs. non-r...